Massachusetts is currently home to 3155 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)
NCT05051033
Recruiting
This is a prospective, multicenter, open-label, randomized trial comparing mitral valve (MV) transcatheter edge-to-edge repair (TEER) to surgical repair (1:1 ratio) in patients with primary, degenerative mitral regurgitation (MR). The trial will be conducted in the U.S., Canada, Germany and the United Kingdom, and is designed as a strategy trial. Thus, all devices legally marketed for TEER of primary degenerative MR in a particular country are eligible to be used in this trial.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/05/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Mitral Valve Regurgitation
Register for Updates
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
NCT05030545
Recruiting
This research study aims to learn more about the impact the hormone aldosterone on the heart. Primary aldosteronism is a condition where the body's adrenal glands make too much of the hormone aldosterone, which can cause high blood pressure and increase the risk of heart and kidney disease. Treatment with medications that block aldosterone can reduce that risk. This study is trying to learn whether treatment with a medication that blocks aldosterone can improve heart function in people who make... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/05/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Primary Aldosteronism, Hypertension
Register for Updates
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
NCT04045665
Recruiting
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their ba... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations
NCT03396341
Recruiting
The purpose of this study is to describe how women with BRCA1/2 mutations react to genetic risk modifier testing, and to examine how they make decisions about their healthcare.
Gender:
FEMALE
Ages:
25 years and above
Trial Updated:
02/05/2025
Locations: Dana Farber Cancer Institute (Data Collection Only), Boston, Massachusetts
Conditions: Genetic Testing, BRCA1/2
Register for Updates
Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
NCT06817395
Recruiting
Individuals with immune thrombocytopenia (ITP) frequently report difficulties with attention and memory. The main question this study seeks to answer is: Do patients with ITP have evidence of cognitive impairment as detected by a cognitive function test battery? To address this issue, participants will take a cognitive function test and complete surveys on quality of life, fatigue, depression, and cognitive symptoms. The primary aim of the study is to evaluate for the presence and extent of co... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Immune Thrombocytopenia
Register for Updates
Synbiotic to Attenuate Resorption of the Skeleton
NCT06389539
Recruiting
This randomized, double blind, placebo controlled clinical trial will test the efficacy of a probiotic/prebiotic combination ("synbiotic") on the skeleton in older women.
Gender:
FEMALE
Ages:
60 years and above
Trial Updated:
02/04/2025
Locations: Hebrew SeniorLife, Roslindale, Massachusetts
Conditions: Osteoporosis, Inflammation, Aging
Register for Updates
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
NCT06262113
Recruiting
The goal of this fully decentralized, randomized controlled trial is to compare the efficacy of two educational interventions for individuals with Neurofibromatosis 1 (NF1). The primary objective of the study is to determine which intervention leads to higher rates of evidenced-based health screenings for NF1 patients in primary care settings. Adults with NF1 and parents/guardians of children with NF1 from across the U.S. who do not go to a specialized NF clinic and who have an upcoming annual... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/04/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Neurofibromatosis 1
Register for Updates
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
NCT05821959
Recruiting
Part A of this trial will evaluate the safety and tolerability of a single unilateral administration of one of two dose levels of AAVAnc80-hOTOF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
Gender:
ALL
Ages:
All
Trial Updated:
02/04/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Sensorineural Hearing Loss, Bilateral
Register for Updates
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT05691504
Recruiting
This phase I trial tests the safety, side effects, and best dose of combination therapy with pelcitoclax (APG-1252) and cobimetinib in treating patients with ovarian and endometrial cancers that have come back after a period of improvement (recurrent). APG-1252 is a drug that inhibits activity of proteins that prevent cell death, leading to increased cell death and reduced cell growth. Cobimetinib is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a cla... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Dana-Farber - Harvard Cancer Center LAO, Boston, Massachusetts
Conditions: Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Advanced Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Platinum-Resistant Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Register for Updates
Surgical Pembro +/- Olaparib W TMZ for RGBM
NCT05463848
Recruiting
This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment. The names of the study interventions involved in this study are/is: * Pembrolizumab * Olaparib * Temozolomide (Temodar)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Glioblastoma, Recurrent Glioblastoma
Register for Updates
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
NCT05076175
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
02/04/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Colitis, Ulcerative
Register for Updates
Resilience to Sleep Deprivation and Changes in Sleep Architecture in Shoonya Meditators
NCT05026541
Recruiting
This study aims to investigate the effect of a 15-minute meditation practice on sleep architecture and high-frequency Heart Rate Variability (HF-HRV), as well as cognitive performance after both a well-rested and sleep-deprived night.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
02/04/2025
Locations: Beth Israel Deaconess Medical Centre, Boston, Massachusetts
Conditions: Sleep, Sleep Deprivation, Cognitive Change
Register for Updates